Breaking News

WCCT Global Appoints CFO

By Kristin Brooks | February 4, 2014

Peters brings extensive industry experience

Dave Peters has been appointed chief financial officer of WCCT Global and joins the executive team. Mr. Peters has more than 17 years of clinical research experience. He joins the company from inVentiv Health where he held several senior positions, including chief financial officer of the CRO segment and senior vice president of commercial and corporate development. Mr. Peters also spent 15 years with ICON Clinical Research, most recently as senior vice president of global finance, where he was on the senior team that took ICON through their IPO and helped grow the business to more than $1 billion in revenue. During his time with both organizations he negotiated and structured more than 30 strategic and preferred partnership agreements with organizations ranging from small biotech companies to large pharmaceutical companies. He also evaluated, executed and integrated numerous acquisitions.
WCCT Global's chief executive officer Dr. Kenneth Kim said, "Dave's extensive wealth and experience in the CRO industry will be instrumental as we continue to provide unique service offerings for the industry. His arrival positions the company well to be the preferred full service drug development specialty CRO in the industry."
  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems